close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
News headline image
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era
Via MarketMinute
Topics Earnings Economy Intellectual Property
Tickers AMGN LLY MCRB NSRGY
Exposures Economy Financial Intellectual Property
How to prep your car for safer winter driving
Via Brandpoint
Topics Product Recall
Exposures Legal Product Safety
News headline image
Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms ↗
Via Investor's Business Daily
Exposures Product Safety
News headline image
Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗
Via Stocktwits
Tickers ALT
Exposures Product Safety
News headline image
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Ignore
Via StockStory
Tickers DXCM GOLF ODFL
Exposures Product Safety
News headline image
Morris R. Heney Launches Travels with Rina
Via AB Newswire
Topics Bonds Product Recall
Exposures Debt Markets Legal Product Safety
News headline image
Agentic AI in Healthcare: The Next Frontier Beyond Generative AI
Via AB Newswire
Topics Artificial Intelligence
Tickers IBM
Exposures Artificial Intelligence Product Safety
News headline image
Novo Nordisk Files FDA Application For Weekly Combination Obesity Shot ↗
Via Benzinga
Exposures Product Safety
News headline image
FDA Approves J&amp;J&#39;s New 5-Minute Injection For Lung Cancer ↗
Via Benzinga
Tickers JNJ
Exposures Product Safety
News headline image
Takeda&#39;s Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen&#39;s Drug ↗
Via Benzinga
Exposures Product Safety
News headline image
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗
Via Stocktwits
Tickers JGRO LLY QUSA VKTX
Exposures Product Safety
News headline image
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report ↗
Via Benzinga
Exposures Product Safety
News headline image
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
Via PredictStreet
Topics Economy World Trade
Tickers BLK GS LLY MS NVO PFE
Exposures Interest Rates Product Safety Tariff
News headline image
Medline Industries (MDLN) Deep-Dive: The $54 Billion Return of a Healthcare Titan
Via PredictStreet
Topics Artificial Intelligence Earnings Economy
Tickers BX CAH CG COR MCK MDLN
Exposures Artificial Intelligence Financial Pension
News headline image
Edison Issues Report on MindMaze Therapeutics (MMTX)
Via Newsfile
Exposures Product Safety
News headline image
Envoy Medical Reaches Enrollment Milestone in Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
Via Newsfile
Tickers ASX:COH COCH
Exposures Product Safety
News headline image
Merck Scores FDA Fast-Track Review For Key Cholesterol And Cancer Drugs With Multibillion-Dollar Potential: Report ↗
Via Stocktwits
Tickers DUHP MRK QUSA
Exposures Product Safety
News headline image
Why CONMED (CNMD) Stock Is Trading Up Today
Via StockStory
Topics Initial Public Offering
Tickers AAPL CNMD MSFT
Exposures Product Safety Securities Market
News headline image
Operational Resilience: Houston Warehousing Built for Protection and Compliance
Via GetFeatured
Exposures Product Safety
News headline image
VYNE Therapeutics: A New Chapter in Autoimmune Disease with Yarrow Bioscience
Via PredictStreet
Tickers VYNE
Exposures Product Safety
News headline image
Nyxoah SA (NASDAQ: NYXH): A Deep Dive into its Bilateral Approach to Sleep Apnea
Via PredictStreet
Topics Initial Public Offering Intellectual Property
Tickers NYXH
Exposures Intellectual Property Product Safety Securities Market
News headline image
FDA Approves Brain Tumor Warning For Pfizer&#39;s Depo-Provera Amid Lawsuit ↗
Via Benzinga
Topics Lawsuit
Tickers PFE
Exposures Financial Legal Product Safety
News headline image
QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm
Via NewMediaWire
Tickers QURE
Exposures Product Safety
News headline image
QURE INVESTIGATION: Kessler Topaz Meltzer &amp; Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm
Via TheNewswire.com
Tickers QURE
Exposures Product Safety
News headline image
FDA Approves GSK&#39;s Drug, Targets Severe Asthma With Two Doses Per Year ↗
Via Benzinga
Exposures Product Safety
News headline image
Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing ↗
Via Benzinga
Exposures Product Safety
News headline image
Silicon’s Shield: Why Cybersecurity is the Linchpin of the Global Semiconductor Industry
Via TokenRing AI
Topics Artificial Intelligence Economy Hacking
Tickers AAPL AMAT AMD GOOGL INTC MCHP
Exposures Artificial Intelligence Information Security Intellectual Property
News headline image
NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results With Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin & Total Revenue Growth of 163% to $9.1 Million for Fiscal Year 2025
Via NewMediaWire
Topics Intellectual Property
Tickers NMTC
Exposures Intellectual Property Product Safety
NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results With Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin &amp; Total Revenue Growth of 163% to $9.1 Million for Fiscal Year 2025
Via TheNewswire.com
Topics Intellectual Property
Tickers NMTC
Exposures Intellectual Property Product Safety
News headline image
RecallKing™ Launches Innovative Public Safety App to Deliver Personalized, Real-Time Product Recall Alerts
Via Get News
Topics Product Recall
Exposures Legal Product Safety
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today